Baseline data on distribution of human papillomavirus (HPV) genotypes in cervical samples of gynecological patients before implementation of population-based HPV vaccination program in Poland
Abstract
Objectives: Free-of-charge vaccination against human papillomavirus (HPV) of 12–13-year-old teenagers was introduced on the 1st of June 2023 in Poland. Data on baseline HPV genotype cervical distribution are crucial to evaluate potential changes after full implementation of the vaccination program. We aimed at evaluating the status of HPV infection and distribution of HPV genotypes in cervical cytology of gynecological patients tested in one of the largest HPV laboratories in Poland. Material and methods: Data on all HPV tests performed in ALAB Laboratoria Sp. z o. o. in Poland in 2018–2021 were analyzed, focusing on tests that identified genotypes: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 70, 73, 81, 82, 83, 89. Distribution of HPV genotypes was assessed among HPV-positive women. Results: Among 11.151 medical records retrieved in women with valid HPV test results, 5.681 were positive (50.9%), of whom 2.929 were infected with a single genotype (51.6%). At least one high-risk (HR) genotype was detected in 4.351 women (76.6%). Among all HPV-positive women, the most common HR genotypes were HPV-16, HPV-31 and HPV-66 (24.0%, 11.3%, 11.3%, respectively). HPV-53 was the most prevalent among non-HR types (10.5%). Conclusions: HPV-16 followed by HPV-31 and HPV-66 were the most frequent genotypes in the studied cohort. These results may be compared with the same methodology after full roll-out of HPV vaccination program in the future to track potential changes in HPV genotype distribution.
Keywords: human papillomavirus genotypeshuman papillomavirus vaccine
References
- HPV information Centre. https://hpvcentre.net/ (17.01.2023).
- de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007; 7(7): 453–459.
- Walboomers J, Jacobs M, Manos M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of Pathology. 1999; 189(1): 12–19, doi: 10.1002/(sici)1096-9896(199909)189:1<12::aid-path431>3.0.co;2-f.
- Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999; 354(9172): 20–25.
- Bouvard V, Baan R, Straif K, et al. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009; 10(4): 321–322.
- IARC monographs on the evaluation of carcinogenic risks to humans. Analytica Chimica Acta. 1996; 336(1-3): 229–230.
- de Sanjose S, Quint WGv, Alemany L, et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11): 1048–1056.
- Taebi M, Riazi H, Keshavarz Z, et al. Knowledge and Attitude Toward Human Papillomavirus and HPV Vaccination in Iranian Population: A Systematic Review. Asian Pac J Cancer Prev. 2019; 20(7): 1945–1949.
- Macios A, Didkowska J, Wojciechowska U, et al. Risk factors of cervical cancer after a negative cytological diagnosis in Polish cervical cancer screening programme. Cancer Med. 2021; 10(10): 3449–3460.
- Uchwała nr 10 Rady Ministrów z dnia 4 lutego 2020 r. w sprawie przyjęcia programu wieloletniego pn. Narodowa Strategia Onkologiczna na lata 2020-2030 M.P. 2020 r. poz. 189.
- Nowakowski A, Jach R, Szenborn L, et al. Recommendations of the Polish Society of Gynaecologists and Obstetricians, Polish Paediatric Society, Polish Society of Family Medicine, Polish Society of Vaccinology, Polish Society of Oncological Gynaecology and Polish Society of Colposcopy and Pathophysiology of the Uterine Cervix on prophylactic vaccinations against infections with human papillomaviruses in Poland. Ginekol Pol. 2022 [Epub ahead of print].
- Ogembo RK, Gona PN, Seymour AJ, et al. Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis. PLoS One. 2015; 10(4): e0122488.
- Martins TR, Mendes de Oliveira C, Rosa LR, et al. HPV genotype distribution in Brazilian women with and without cervical lesions: correlation to cytological data. Virol J. 2016; 13: 138.
- Freire-Salinas J, Benito R, Azueta A, et al. Genotype distribution change after human papillomavirus vaccination in two autonomous communities in Spain. Front Cell Infect Microbiol. 2021; 11: 633162.
- Bretagne CH, Jooste V, Guenat D, et al. Prevalence and distribution of HPV genotypes and cervical-associated lesions in sexually active young French women following HPV vaccine. J Gynecol Obstet Hum Reprod. 2018; 47(10): 525–531.
- Smith JS, Melendy A, Rana RK, et al. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health. 2008; 43(4 Suppl): S5–25, S25.e1.
- StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP.
- R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/ (3.04.2024).
- Cornall AM, Saville M, Pyman J, et al. HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination. Vaccine. 2020; 38(40): 6304–6311.
- Shilling H, Garland SM, Atchison S, et al. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction. Vaccine. 2021; 39(34): 4856–4863.
- Subasinghe AK, Wark JD, Phillips S, et al. Quadrivalent human papillomavirus vaccination successfully reduces the prevalence of vaccine-targeted genotypes in a young, vaccine-eligible-age sample of Australian females. Sex Health. 2020; 17(6): 510–516.
- Bretagne CH, Jooste V, Guenat D, et al. Prevalence and distribution of HPV genotypes and cervical-associated lesions in sexually active young French women following HPV vaccine. J Gynecol Obstet Hum Reprod. 2018; 47(10): 525–531.
- Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010; 202(12): 1789–1799.
- de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007; 7(7): 453–459.
- Poljak M, Seme K, Maver PJ, et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine. 2013; 31 Suppl 7: H59–H70.
- Učakar V, Poljak M, Klavs I. Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: a cervical cancer screening based study. Vaccine. 2012; 30(2): 116–120.
- Kjaer SK, Breugelmans G, Munk C, et al. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer. 2008; 123(8): 1864–1870.
- Bardin A, Vaccarella S, Clifford GM, et al. Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur J Cancer. 2008; 44(4): 557–564.
- Przybylski M, Pruski D, Millert-Kalinska S, et al. Genotyping of human papillomavirus DNA in Wielkopolska region. Ginekol Pol. 2022; 93(7): 546–551.
- Przybylski M, Pruski D, Wszołek K, et al. Prevalence of HPV and assessing type-specific HPV testing in cervical high-grade squamous intraepithelial lesions in Poland. Pathogens. 2023; 12(2).
